Compare BWFG & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BWFG | GLSI |
|---|---|---|
| Founded | 2002 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.0M | 123.9M |
| IPO Year | N/A | 2020 |
| Metric | BWFG | GLSI |
|---|---|---|
| Price | $46.88 | $23.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $53.00 | $50.00 |
| AVG Volume (30 Days) | 62.9K | ★ 785.7K |
| Earning Date | 01-23-2026 | 11-14-2025 |
| Dividend Yield | ★ 1.70% | N/A |
| EPS Growth | ★ 88.52 | N/A |
| EPS | ★ 3.66 | N/A |
| Revenue | ★ $94,282,000.00 | N/A |
| Revenue This Year | $68.08 | N/A |
| Revenue Next Year | $13.72 | N/A |
| P/E Ratio | $12.83 | ★ N/A |
| Revenue Growth | ★ 30.93 | N/A |
| 52 Week Low | $26.39 | $7.78 |
| 52 Week High | $51.54 | $30.82 |
| Indicator | BWFG | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 46.72 | 72.94 |
| Support Level | $44.95 | $18.54 |
| Resistance Level | $48.00 | $21.87 |
| Average True Range (ATR) | 1.48 | 3.60 |
| MACD | -0.36 | 0.60 |
| Stochastic Oscillator | 23.37 | 63.37 |
Bankwell Financial Group Inc is a bank holding company, engaged in providing financial products and services. It offers products related to commercial lending, retail lending, depository services, and others. The bank's commercial lending products includes owner-occupied commercial real estate loans, commercial real estate investment loans, commercial loans to small and mid-sized businesses and real estate construction and development loans. The retail lending products include residential mortgage loans, home equity lines of credit, and consumer installment loans. Its depository products include checking, savings, money market, certificates of deposit, noninterest-bearing demand, and time deposits.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.